Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 26Phase 1/2 22Phase 3 14Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 3Lymphoma 3Recurrence 2Lymphoma, B-Cell 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia 1Immunoproliferative Disorders 1

Interventions

Rituximab 2loncastuximab tesirine 1etoposide phosphate 1blinatumomab 1Tubercidin 1Immunotherapy, Adoptive 1Ifosfamide 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, B-Cell × Rituximab × Clear all
NCT05991388 2026-02-20

Glo-BNHL

University of Birmingham

Phase 2/3 Recruiting
210 enrolled
Lymphoid

Lymphoma, B-Cell

NCT00147121 2016-09-22

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Japan Clinical Oncology Group

Phase 2/3 Completed
300 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡